INS and Hypoglycemia: A 2018 study [109] looked at data from 38 clinical studies of acute nasal insulin administration that had dosed 1092 individuals and a further 18 studies in 832 individuals for periods between 21 days and 9.7 years and found no evidence of symptomatic hypoglycemia or serious adverse events, while 10 of the acute studies reported minor, temporary reductions in blood glucose and one report of minor glucose reduction in the chronic study.